Desmoplastic-resistant prostate cancer is one of the most difficult and important aspects of prostate cancer treatment, and progress has been slow over the past few decades. A breakthrough in the treatment of destructive prostate cancer was achieved in 2004 when docetaxel was first shown to prolong the survival of patients with metastatic destructive prostate cancer. Since 2010, significant advances have been made in the treatment of destructive prostate cancer, with several drugs proven in phase III clinical studies to prolong overall or progression-free survival in patients with destructive prostate cancer, including four drugs that have been approved by the U.S. Food and Drug Administration (FDA) for clinical use: (1) Cabazitaxel: a chemotherapeutic agent that has been approved by the FDA (2) Abiraterone: an anti-androgen drug, approved by the FDA; (3) Provenge (Sipuleucel-T): an immunotherapy drug, approved by the FDA; (4) Ra-223: a radioisotope (emits alpha particles); (5) Denosumab: a monoclonal antibody (bone targeting drug), approved by the FDA.